1. Baba M (1995) Expression of MDR gene and drug resistance. BIO Clin 10:76
2. Biedler JL, Riehm H (1970) Cellular resistance to actinomycin D, in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res 30:1174–1184
3. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, De Lena M, Tancini G, Bajetta E, Musumeci R, Veronesi U (1976) Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294:405–410
4. Chevillard S, Pouillart P, Beldjord C, Asselain B, Beuzeboc P, Magdelenat H, Vielh P (1996) Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer 77:292–300
5. Chevillard S, Lebeau J, Pouillart P, de Thoma C, Beldjord C, Asselain B, Klijainenko J, Fourquet A, Magdelenat H, Vielh P (1997) Biological clinical significance of concurrent p53 gene alterations, MDR1 gene expression, S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy. Clin Cancer Res 3:2471–2478